CIK: 0001845151
Total reported value
$81.3M
Reporting period: 2025-09-30 · Number of holdings: 3
MWG Management Ltd. disclosed 3 holdings in its latest 13F filing for the period ending 2025-09-30, with total reported value of $81.3M and a quarterly turnover rate of 66.5%.
Browse other institutions with under $100M AUMBrowse other institutions starting with "M"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim BEAM
0.0% $10.7M
Add PRME
0.0% $6.4M
New buy LYEL
Sold out LYEL
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BEAM | Beam Therapeutics INC | Stock-Other | 67.66% | -7.78% | — | |
| 2 | LYEL | Lyell Immunopharma INC | Stock-Other | 20.13% | +20.13% | NEW | |
| 3 | PRME | Prime Medicine INC | Stock-Other | 12.21% | +6.13% | — |
Performance for Q3 2026
-14.3%
Performance Last 4 Quarters
+38.6%
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2025-09-30 | 3 | $81.3M | 67 | |
| 2025-06-30 | 3 | $51.9M | 0 | |
| 2025-03-31 | 3 | $58.7M | 100 | |
| 2024-12-31 | 3 | $74.4M | 0 | |
| 2024-09-30 | 3 | $90.3M | 0 | |
| 2024-06-30 | 3 | $91.6M | 0 | |
| 2024-03-31 | 3 | $135.1M | 0 | |
| 2023-12-31 | 3 | $118.9M | 0 | |
| 2023-09-30 | 3 | $103.2M | 0 | |
| 2023-06-30 | 3 | $165.3M | 0 | |
| 2023-03-31 | 3 | $142.0M | 0 | |
| 2022-12-31 | 3 | $195.9M | 0 | |
| 2022-09-30 | 2 | $259.6M | 0 | |
| 2022-06-30 | 2 | $222.3M | 0 | |
| 2022-03-31 | 2 | $236.3M | 0 | |
| 2021-12-31 | 2 | $343.1M | 0 | |
| 2021-09-30 | 4 | $824.7M | 0 | |
| 2021-06-30 | 4 | $1.0B | 100 | |
| 2021-03-31 | 2 | $205.8M | 100 | |
| 2020-12-31 | 2 | $157.7K | 0 |
MWG Management Ltd.'s most significant position changes for 2025-09-30: New buy: Lyell Immunopharma INC (LYEL); Sold out: Lyell Immunopharma, Inc. (LYEL).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PRME | Prime Medicine INC | +6.1% | — | Unchanged |
| 2 | BEAM | Beam Therapeutics INC | -7.8% | — | Unchanged |
| 3 | LYEL | Lyell Immunopharma INC | — | NEW | New buy |
| 4 | LYEL | Lyell Immunopharma, Inc. | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2025-09-30 | 2025-11-12 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-13 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-08 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-13 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-14 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-17 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001383221
Total reported value
$81.3M
51 stks
2016-09-30
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001854024
Total reported value
$81.3M
5 stks
2025-09-30
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001912226
Total reported value
$81.4M
14 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0002111120
Total reported value
$72.4M
3 stks
2025-12-31
Stale — no recent filing
3 of the top 5 holdings overlap, including Beam Therapeutics INC
CIK 0001274403
Total reported value
$677.1M
10 stks
2026-03-31
1 of the top 5 holdings overlap, including Beam Therapeutics INC
CIK 0001550093
Total reported value
$266.8M
10 stks
2026-03-31
1 of the top 5 holdings overlap, including Lyell Immunopharma INC